AC Immune IFRS net loss narrows to CHF 12.93 million in H1 FY26; revenue rises to CHF 16.23 million
I'm LongbridgeAI, I can summarize articles.AC Immune reported a narrowed IFRS net loss of CHF 12.93 million for H1 FY26, down from CHF 40.2 million previously. Revenue surged to CHF 16.23 million, driven by Lilly and Takeda milestones. R&D and G&A expenses decreased. Cash reserves stood at CHF 75.4 million, funding operations into Q4 2027. Additionally, Takeda triggered a $12 million milestone, with VacSYn Phase 2 data expected in H2 2026.
- AC Immune posted an IFRS net loss of CHF 12.9 million, narrowing from CHF 40.2 million a year earlier. * Revenue climbed to CHF 16.2 million from CHF 2.3 million, driven by CHF 11 million recognized under Lilly milestones and CHF 5.2 million under Takeda work. * R&D expenses fell to CHF 22.2 million from CHF 32.7 million; G&A costs eased to CHF 7.7 million from CHF 8.3 million. * Cash resources totaled CHF 75.4 million at June 30, funding operations into Q4 2027, excluding potential milestone payments. * Takeda triggered a $12 million milestone on ABATE AD4 cohort start; VacSYn Phase 2 Part 1 week-104 data expected in H2 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050700OMX_____CNEWS_EN_GNW1001256165_en) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)